Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
M. Hashemi,Sara Etemad,Sahar Rezaei,Setayesh Ziaolhagh,Romina Rajabi,Parham Rahmanian,Soheila Mohammadi Abdi,Zeinab Khazaei Koohpar,Reihaneh Rafiei,Behnaz Raei,Fatemeh Ahmadi,Shokooh Salimimoghadam,Amir Reza Aref,Mohammad Arad Zandieh,Maliheh Entezari,Afshin Taheriazam,Kiavash Hushmandi +16 more
74
TL;DR: In this paper , the function of PTEN/PI3K/Akt/mTOR axis in GBM progression is evaluated and new insights for targeting this axis in effective GBM treatment are provided.
read more
About: This article is published in Biomedicine & Pharmacotherapy. The article was published on 01 Feb 2023. and is currently open access. The article focuses on the topics: Medicine & PTEN.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
TL;DR: TriAP1 as mentioned in this paper is a novel p53 downstream inhibitor of apoptosis, which is the homolog of yeast mitochondrial intermembrane protein MDM35 and can play a tumor-promoting role by blocking the mitochondriadependent apoptosis pathway.
24
Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer
Chao Peng,Yang Liu +1 more
TL;DR: Regulation of ferroptosis by PI3K/Akt signaling pathway in cancer is a promising therapeutic axis that explores the interplay between dysregulated PI3K/Akt pathway and ferroptosis for cancer treatment.
20
Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway
TL;DR: Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutllariae Radix and is demonstrated to have anti-tumor properties in colon cancer as discussed by the authors .
Amino Acid Transporters Within the Solute Carrier Superfamily: Underappreciated Proteins and Novel Opportunities for Cancer Therapy.
Kiavash Hushmandi,Behzad Einollahi,Seyed Hassan Saadat,E. H. Clarissa Lee,M. Ramezani Farani,Elena Okina,Yun Suk Huh,Noushin Nabavi,Shokooh Salimimoghadam,Alan Prem Kumar +9 more
TL;DR: This review explores the role of amino acid transporters within the Solute Carrier superfamily in cancer, highlighting their impact on tumor progression and potential as novel therapeutic targets, with a focus on the intricate connections between amino acids, SLCs, and cancer biology.
15
Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Xueqing Kong,Jinyi Zhang,Shuwei Chen,Xianyang Wang,Qing Xi +4 more
TL;DR: Immune checkpoint inhibitors (ICIs) are promising cancer treatments targeting specific immune checkpoints, such as CTLA-4 and PD-1. However, resistance and tolerance to treatment are major challenges. Ongoing research focuses on identifying additional ICIs and synergistic inhibitory receptors to enhance treatment effectiveness.
14
References
Cancer statistics, 2010
TL;DR: The American Cancer Society as mentioned in this paper estimated the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data regarding cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from National Center for Health Statistics.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
7.4K
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao,Qiulian Wu,Roger E. McLendon,Yueling Hao,Qing Ming Shi,Anita B. Hjelmeland,Mark W. Dewhirst,Darell D. Bigner,Jeremy N. Rich +8 more
TL;DR: This work shows that cancer stem cells contribute to glioma radioresistance through preferential activation of the DNA damage checkpoint response and an increase in DNA repair capacity, and suggests that CD133-positive tumour cells could be the source of tumour recurrence after radiation.
6.4K
Interleukin 17–producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages
Laurie E. Harrington,Robin D. Hatton,Paul R. Mangan,Henrietta Turner,Theresa L. Murphy,Kenneth M. Murphy,Casey T. Weaver +6 more
TL;DR: Findings provide a basis for understanding how inhibition of IFN-γ signaling enhances development of pathogenic TH-17 effector cells that can exacerbate autoimmunity.
5K
The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate
Tomohiko Maehama,Jack E. Dixon +1 more
TL;DR: It is demonstrated that overexpression of PTEN, a putative tumor suppressor, reduced insulin-induced PtdIns(3,4,5)P3 production in human 293 cells without effecting insulin- induced phosphoinositide 3-kinase activation.
3.2K